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Abstract: Eye care professionals should have access to high quality clinical practice guidelines
that ideally are underpinned by evidence from robust systematic reviews of relevant research.
The aim of this study was to identify clinical guidelines with recommendations pertaining to dietary
modification and/or nutritional supplementation for age-related macular degeneration (AMD), and
to evaluate the overall quality of the guidelines using the Appraisal of Guidelines for Research and
Evaluation II (AGREE II) instrument. We also mapped recommendations to existing systematic
review evidence. A comprehensive search was undertaken using bibliographic databases and other
electronic resources for eligible guidelines. Quality appraisal was undertaken to generate scores
for each of the six AGREE II domains, and mapping of extracted nutritional recommendations
was performed for systematic reviews published up to March 2017. We identified 13 national and
international guidelines, developed or updated between 2004 and 2019. These varied substantially
in quality. The lowest scoring AGREE II domains were for ‘Rigour of Development’, ‘Applicability’
(which measures implementation strategies to improve uptake of recommendations), and ‘Editorial
Independence’. Only four guidelines used evidence from systematic reviews to support their
nutritional recommendations. In conclusion, there is significant scope for improving current Clinical
Practice Guidelines for AMD, and guideline developers should use evidence from existing high
quality systematic reviews to inform clinical recommendations.
Keywords: clinical practice guidelines; systematic reviews; age-related macular degeneration;
nutritional supplements; diet; nutrition; AGREE II
1. Introduction
Age-related macular degeneration (AMD) is an ocular disease affecting the central area of the
retina (the macula), which is responsible for high-resolution daytime vision [1]. In the early stages
of AMD, the macula shows characteristic sub-retinal lipoprotein deposits, known as drusen, and the
monolayer of pigmented cells beneath the retina (retinal pigment epithelium) shows areas of hypo- and
hyper-pigmentation. As the disease progresses, the retinal pigment epithelium can become atrophic,
with secondary dysfunction and a loss of retinal photoreceptors [2]. Less commonly, new blood vessels
grow beneath, or within, the retina; these vessels have a tendency to leak, causing disruption to
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the macular architecture and ultimately scar formation (neovascular AMD). Early AMD is typically
asymptomatic; however, later stages of AMD can have a significant negative impact on visual function
and quality of life [3]. AMD is currently the leading cause of severe vision impairment among people
aged 50 and over in high-income countries [4]. With increasing life expectancy these numbers are
projected to increase substantially in the future.
AMD is a complex disorder with several non-modifiable and modifiable risk factors [5]. The retina
is particularly susceptible to oxidative stress, as a result of its high oxygen consumption and exposure
to light; animal and cell culture studies have identified oxidative stress as a contributory factor for
the development of AMD [6]. A large body of observational and experimental research in humans
has investigated the association between dietary antioxidants and AMD, in particular whether an
increased intake of antioxidant vitamin and minerals or specific carotenoids can prevent or slow the
progression of the disease [7,8]. The role of particular essential fatty acids has also been investigated,
including exploiting the anti-inflammatory properties of long-chain omega-3 fatty acids.
Based on accumulating research evidence, dietary modification and/or nutritional supplementation
has been proposed as a simple and potentially cost-effective strategy for modifying the risk of AMD.
Although there is a large body of research in this area, the quality of studies is highly variable and
conflicting results have been reported. These factors pose challenges for clinicians, when attempting
to provide evidence-based recommendations to patients about the relative risks and benefits of
nutrition-based interventions. Clinical practice guidelines can be used to aid clinical decision-making
in such circumstances. These documents should contain recommendations that are informed by a
systematic review of the available research evidence, and a consideration of the benefits and harms
of alternative interventions [9]. In the process of guideline development, developers either elect to
perform their own systematic review of the literature, or to instead integrate the results from previously
published reviews. Systematic reviews involve a process of systematically identifying, appraising and
synthesising findings from all relevant research studies relating to a particular research question, with
the intent of minimising the potential for bias. The objectives of the present study were to:
(1) Identify clinical practice guidelines for AMD that contain nutritional recommendations, based
upon a systematic literature search;
(2) Evaluate the quality of these guidelines using the Appraisal of Guidelines for Research and
Evaluation II (AGREE II) tool; and
(3) Map clinical practice guideline recommendations, as related to nutrition and AMD, to relevant
systematic reviews.
2. Materials and Methods
2.1. Eligibility Criteria
We included national and international clinical practice guidelines for AMD that contained
nutritional recommendations, including dietary modification or nutritional supplementation,
as strategies to prevent or slow the progression of the disease.
2.2. Search Strategy
We searched the Ovid MEDLINE and Embase bibliographic databases from January 1999 to
January 2019 using search filters for identifying clinical guidelines that were developed by the Canadian
Agency for Drugs and Technologies in Health (https://www.cadth.ca) (see Supplementary Materials).
In addition to the bibliographic database searches, we also searched Guideline Central Summaries
(https://www.guidelinecentral.com/summaries/) and the Turning Research into Practice (TRIP) database
(https://www.tripdatabase.com/), and undertook a search of the webpages of national and international
professional organisations for ophthalmology and optometry. The search was not limited by language
and we used Google Translate to extract recommendations and appraise guidelines that were not
written in English.
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2.3. Study Selection and Data Extraction
Following removal of duplicates, two reviewers (JL/LD) independently screened the titles and
abstracts identified from the bibliographic searches and resolved any discrepancies by discussion and
consensus. We obtained full-text copies of potentially eligible guidelines and these were independently
assessed by all three authors, working in pairs, to determine whether they met the inclusion criteria.
Reasons for exclusion were documented at this stage. Two reviewers (all three authors working in
pairs) independently extracted general characteristics of each guideline (e.g., author/organisation,
country, year of publication, target audience) and details of the specific nutritional recommendations.
2.4. Appraisal of Clinical Guidelines
The quality of each clinical guideline was independently evaluated by two reviewers (all three
authors working in pairs) using the Appraisal of Guidelines for Research and Evaluation (AGREE)
II tool (https://www.agreetrust.org/). The AGREE II instrument evaluates the process of practice
guideline development, and the quality of reporting, using 21 items organised into six key domains, as
follows: (1) Scope and Purpose; (2) Stakeholder Involvement; (3) Rigour of Development; (4) Clarity
of Presentation; (5) Applicability; and (6) Editorial Independence. Table 1 provides further details
about the content of these domains. Each item within the AGREE II tool comprises a quality
statement/concept, which is scored using a 7-point Likert rating scale. A score of ‘1’ was given when
there was no information that was relevant to the item or where the concept was very poorly reported.
A score of ‘7’ was given if the quality of reporting met the full criteria, as defined in the AGREE II
User’s Manual. The overall scores for each of the six domains were calculated by summing up all
the scores of the individual items for that domain, and then scaling the total as a percentage of the
maximum possible score for each domain. Therefore higher scores indicate higher guideline quality.
An intra-class correlation coefficient (ICC) was used to evaluate overall inter-rater agreement.
Table 1. Clinical guideline quality domains used in the Appraisal of Guidelines for Research and
Evaluation II (AGREE II) tool.
Domain Content
Scope and Purpose (3 items) Concerned with the overall aim of the guideline, the specific health questions,and the target population
Stakeholder Involvement (3 items) Focuses on the extent to which the guideline was developed by the appropriatestakeholders and represents the views of its intended users
Rigour of Development (8 items) Relates to the process used to gather and synthesize the evidence, the methodsto formulate the recommendations, and to update them
Clarity of Presentation (3 items) Deals with the language, structure, and format of the guideline
Applicability (4 items) Pertains to the likely barriers and facilitators to implementation, strategies toimprove uptake, and resource implications of applying the guideline
Editorial Independence (2 items) Concerned with the formulation of recommendations not being unduly biasedwith competing interests
2.5. Mapping Clinical Guideline Recommendations to Systematic Review Evidence
Given the predominance of systematic reviews in the hierarchy of clinical evidence [10], we
undertook an exercise to map the extracted guideline recommendations relating to diet or nutritional
supplementation, in the context of AMD, to the evidence derived from systematic reviews. We also
assessed whether recommendations were linked to particular citations (e.g., systematic reviews,
individual randomised controlled trials (RCTs), or other study designs). To identify relevant systematic
reviews on nutritional interventions for AMD we used two recently published studies [11,12] that
identified and critically appraised systematic reviews of AMD interventions. Lindsley et al. [11]
identified 47 systematic reviews published between 2001 and 2014, of which 9 (19%) evaluated dietary
supplements. A more recent study by Downie and colleagues [12] found 71 systematic reviews
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published between 2003 and 2017, with 10 (12%) relating to nutritional interventions in AMD. These
studies identified 11 unique reviews [13–23], of which over 50% were published after 2014.
The process of mapping systematic reviews to guideline recommendations relating to nutrition
was performed by a single reviewer and then independently checked by a second reviewer.
3. Results
3.1. Search Results
The searches identified 868 potentially relevant records. Following title and abstract screening,
838 were excluded. After a full-text review of 30 potentially eligible records, 17 were excluded as they
did not contain recommendations for nutritional interventions. Thirteen guidelines were included in
the final analysis. Figure 1 shows the flow diagram for guideline selection.
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able 2 sum arises the characteristics of 13 national guidelines from the Unit d King om [24,25],
United States [26–28], Canada [29,30], Australia [31], New Zealand [32], Spain [33], Germany [34], d
the Philippines [35], and an international ophthalmology guideline [36], that were published between
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2004 and 2019. Three guidelines were produced by government organisations [24,25,32], while the
remainder were developed by professional societies or associations for specific eye care professions.
Table 2. General characteristics of the included age-related macular degeneration (AMD) clinical
practice guidelines.
Organisation Reference Year Country Target Audience
American Optical Association [26] 2004 United States Optometrists
International Council of Ophthalmology [36] 2007 International Optometrists
Spanish Retina and Vitreous Society (SERV) [33] 2009 Spain Ophthalmologists
Canadian Expert Consensus [30] 2012 Canada Ophthalmologists
German Ophthalmological Society (in German) [34] 2014 Germany Ophthalmologists
Eye Health Council of Ontario [29] 2015 Canada Health and eye care professionals
National Health Committee [32] 2015 New Zealand Healthcare professionals involved in thediagnosis and management of AMD
American Academy of Ophthalmology [27] 2015 United States Ophthalmologists
Vitreo-retina Society of the Philippines (VRSP) [35] 2016 Philippines Ophthalmologists
National Institute for Health and Care Excellence
(NICE; Clinical Knowledge Summaries) [24] 2016 United Kingdom Primary care healthcare professionals
Clinical Advisory Committee [28] [28] 2017 United States Optometrists
NICE (NG82) [25] 2018 United Kingdom Healthcare professionals involved in thediagnosis and management of AMD
Optometry Australia [31] 2019 Australia Optometrists
Eight guidelines [24,26–29,31,34,35] provided nutritional recommendations (either positive or
negative) for reducing the risk of developing AMD (primary prevention) (Table 3). Guidelines from
Canada [29], Germany [34], and Australia [31] included recommendations on the value of dietary
modification for primary prevention. With regard to supplements, a guideline produced by an expert
panel of optometrists in the United States [28] recommended the use of xanthophil supplements (lutein,
zeaxanthin, and mesozeaxanthin) in ‘sub-clinical’ AMD and another suggested that supplementation
with antioxidants may be beneficial for those who are nutritionally deficient [26]. Five guidelines
specifically stated that there was evidence that use of high- dose anti-oxidant vitamin and mineral
supplements was not beneficial for primary prevention (Table 3) [24,27,31,34,35].
All of the included guidelines provided recommendations regarding nutritional strategies for
secondary prevention (i.e., slowing the progression of AMD) (Table 4). Five guidelines [24,28,30,31,33]
included dietary advice, consisting of encouraging people with AMD to eat a healthy diet and,
in particular, to increase consumption of foods rich in the macular carotenoids (lutein and zeaxanthin)
and/or eat more oily fish as a source of omega-3 essential fatty acids. With regard to nutritional
supplements, all guidelines addressed the topic of antioxidant vitamin and mineral supplements; the
vast majority referred to supplements containing the combinations of antioxidant vitamins, zinc and
carotenoids used in the Age-Related Eye Disease Studies (AREDS) or AREDS2 studies [7,8]. Only
the U.K. National Institute for Health and Care Excellence (NICE) guideline [25] did not advocate
the use high-dose antioxidant vitamin and mineral supplements for the secondary prevention of
AMD. The NICE guideline committee concluded that “the current clinical evidence was not able to
demonstrate a clear treatment benefit of antioxidant vitamin and mineral supplement for people with
early AMD and was insufficient to make a strong recommendation on the use of these supplements”.
The majority of guidelines acknowledged the risks as well as the benefits of antioxidant vitamin and
mineral supplementation. Although acknowledging the lack of evidence, two guidelines [28,34] stated
that omega-3 fatty acid supplements could be considered. By contrast, the NICE committee [25]
concluded that “omega-3 fatty acid supplementation had no meaningful effect on AMD progression
and visual acuity, and that therefore no recommendations could be made on this topic”.
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3.3. Clinical Guideline Quality Scores
The overall inter-rater agreement on scoring of the individual items was excellent (correlation
coefficient: 0.81 (95% confidence interval (CI) 0.76 to 0.84)).
The quality of each guideline, across each of the AGREE II domains, is shown in Table 5.
The median percentage scores (%) for different domains ranged from 13% to 75%, with substantial
heterogeneity in quality between guidelines. Only two of six domains had a median score over 50%
(‘Scope and Purpose’ and ‘Clarity of presentation’). The lowest scoring domains were ‘Applicability’
(median 13% (range 0 to 98%)), ‘Editorial Dependence’ (median 20.8% (range 0 to 100%)), and Rigour
of Development (median 20.4% (range 9.2 to 95.9%)). For the ‘Rigour of Development’ domain, only
four of the 13 guidelines achieved a score ≥50%; this was largely due to a failure to demonstrate
that systematic methods had been used to search for relevant evidence, no description of the criteria
used for selecting and/or evaluating the evidence, and no information on the methods used by the
developers to formulate recommendations.
3.4. Mapping Clinical Guideline Recommendations to Systematic Review Evidence
We extracted individual recommendations relating to nutritional strategies for both preventing and
slowing the progression of AMD (see Tables 3 and 4 for an overview). For some guidelines, no evidence
was provided to support nutritional recommendations [33,36]. For other guidelines, individual studies
(i.e., RCTs or prospective cohort studies) were cited. Only four guidelines [24,25,30,34] included
evidence from systematic reviews despite the availability of reliable systematic reviews for all of the
extracted nutritional recommendations [13–23].
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Table 3. Nutritional recommendations for primary prevention of age-related macular degeneration (AMD).
Clinical Guideline Dietary Advice Use of Antioxidant orMineral Supplements
Use of Omega-3 Fatty
Acid Supplements
Contraindications or
Side Effects of
Supplements
Systematic Review Cited
with Recommendation
American Optical Association 2004 NR
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rich in carotenoids (lutein and zeaxanthin) and omega-3 fatty acids; 2 Dietary intake of antioxidants, docosahexaenoic acid, and omega-3 fatty acids; 3 Diet high in 
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, recommendation included; NICE, National Institute for Health and Care Excellence; NR, no recommendation. Guideline recommendations: 1 Balanced diet; 2 A diet
high in green, leafy vegetables (rich in antioxidants and carotenoids); 3 A diet high in macular carotenoids (z axanthin and lutein) and omega-3 fatty acids; 4 Antioxidant nutrient
upplements (particul rly for nutritionally defic ent); 5 E of no benefit or a tioxida t vitamin and/or min ral uppl ments or primary revention; 6 Supplement contain ng
xanthophylls (lutein, zeaxa thin, m so-zeax nthin) for ‘sub-clinical’ AMD. 7 Supplements not currently recommended for people with normal ageing changes.
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Use of 
Omega-3 Fatty 
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Supplements 
Contraindications 
or Side Effects of 
Supplements 
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Cited with a 
Recommendation 
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Cli ical Advi ory Committee (United States) 2017 4 7a 9 NR None 
NICE Guideline ( G82) 2018 NR 8 10  Yes 
Opto etry Australia 2019 5 7b NR NR None 
Abb viations: , recomm da ion ncluded; NICE, National Institute for Health and Care Excellence; NR, no reco mendation. Guideline recommendations: 1 Diet 
rich i  carote oids (lutein and zeaxanthin) and omega-3 fat y acids; 2 Dietary intake f ant oxidants, docosahexaenoic acid, and omega-3 fatty acids; 3 Diet high in 
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(AREDS) or AREDS2 supplement r comm nde ; 7b AREDS or AREDS2 supplement may be beneficial, and should be discussed in conjunction with the patient’s 
general medical practitioner. 8 No evidenc  that b nefit of AREDS supplement ou weighs the risk; 9 Omega-3 fatty acid supplement recommended; 10 No evidence 
for benefit of omega-3 fatty acid supplements. 
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Ca adian Expert Consensus 2012 2 7a   Yes 
German Ophthalm logical Society 2014 7a 10  Yes 
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fresh fruit and green, leafy vegetables (rich in antioxidants and carotenoids); 4 Consume oily fish rich in DHA and follow healthier eating styles e.g., Mediterranean 
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for benefit of omega-3 fatty acid supplements. 
  
7a NR NR None
American Academy of Ophthalmology 2015 R
Nutrients 2019, 11, 823 8 of 15 
Table 4. Nutritional recommendati ns for secondary prevention (i.e., slowi g the progression) of age-related cular degenerati n (AMD). 
Clinical Guideline Dietary Advice 
Use of 
Antioxida t 
or Miner l 
Supplements  
Use f 
mega-3 Fatty 
Acid 
Supplements 
Contraindications 
or Side Effects of 
Supplements
Syste atic Review 
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Cli ical Advisory Committe  (United St es) 2017 4 7a 9 NR None 
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Optometry Australia 2019 5 7b NR NR None 
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diet; 5 A diet rich in green leafy vegetables, fish and antioxidants should be encouraged; 6 Antioxidant nutrient supplements; 7a Age-Related Eye Disease Studies 
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Tabl  4  Nutritional r comm ndati ns for s con ary prevention (i.e., slowing the progression) of age-related acular degenerati n (AMD). 
Clinical Guideline Dietary Advice 
Use of 
Antioxidant 
or Mineral 
Supplements  
Use of 
Omega-3 Fatty 
Acid 
Supplements 
Contraindications 
or Side Effects of 
Supplements 
Systematic Review 
Cited with a 
Recommendation 
A erican Optical Association 2004 NR 6 NR  None 
Inter ational Council of Ophthalmology 2007 NR 7a R R e 
Spanish Retina and Vitreous Society 2009 1 7a   None 
Ca adian Expert Consensus 2012 2 7a  Yes 
German Ophth lm logical Society 2014  7a 10  Yes 
Eye Health Council of Ontario (Canad ) 2015 3 7a 10  one 
National Health Committee (New Zealand) 2015 R 7a NR  e 
American Acade y of Ophthalmology 2015  7a R  one 
Vitr o-Re in  Society of he Philippines 2016 NR 7a   e 
NICE Clinical K wle ge Sum ary (CKS) 2016 3 7a NR  Yes 
Cl ical Advisory Committe  (United States) 2017 4 7a 9 NR None 
NICE Guideline (NG82) 2018 NR 8 10  Y s 
Opto etry Australia 019 5 7b NR NR None 
Abbreviations: , e omm nda i n nclud d; NICE, National Institute for H alth and Care Excellence; NR, no r commendation. Guideline recommendations: 1 Diet
rich in carotenoids (lutein and zeaxanthin) and omega-3 fatty acids; 2 Dietary intake of antioxidants, docosahexaenoic acid, and omega-3 fatty acids; 3 Diet high in 
fresh f uit and green, leafy vegetables (rich in antioxi ants and c rotenoids); 4 Consume oily fish ich in DHA and follow healthier eating styles e.g., Mediterranean 
diet; 5 A diet rich in green l afy vegetables, fish and antioxidants should be encourag d; 6 Antioxidant nutrient supplements; 7a Age-Related Eye Disease Studies 
(AREDS) or AREDS2 supplement r commende ; 7b AREDS or AREDS2 supplement may be beneficial, and should be discussed in conjunction with the patient’s 
general medical practitioner. 8 No evidence that benefit of AREDS supplement outweighs the risk; 9 Omega-3 fatty acid supplement recommended; 10 No evidence 
for benefit of omega-3 fatty acid supplements. 
  
None
NICE li ical Knowledge Summary ( KS) 2016
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Table 4. Nutritional recommendations for second y prevention (i.e., slowing t e progression) of age-related macular degeneration (AMD). 
Clinical Guideline Dietary Advic  
Use of 
Antioxidant 
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Use of 
Omega-3 Fatty 
Acid 
Supple nts 
Con raindications 
or Side Effects of 
Supplements 
Systematic Review
Cited with a 
Recommendation 
American Optical Associat on 2004 NR 6 one 
I ternational Council of Ophthalmol g 2007 R R 
Spanish Retina and Vitreous Society 2009 1 7a R one 
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for benefit of omega-3 fatty acid supplements. 
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Tab e 4  Nutritional r comm ndati ns for s con ary prevention (i.e., slowi g the progression) of age-related macular degeneration (AMD). 
Clinical Guideline Dietary Advice 
Use of 
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Supplements  
Use of 
Omega-3 Fatty 
Acid 
Supplements 
Contraindications 
or Side Effects of 
Supplements 
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Cited with a 
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American Optical Association 2004 NR 6 one 
I ternational Council of Ophthalmology 2007 R R 
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Ey  Health Council of Ontario (Ca ad ) 2015 3 7a 10  one 
National Health Committee (New Zealand) 2015 R 7a NR NR None 
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Cl ical Advisory Committe  (United St es) 2017 4 7a 9 NR None 
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rich i  carote oids (lutein and zeaxanthin) and omega-3 fatty acids; 2 Dietary intake of antioxidants, docosahexaenoic acid, and omega-3 fatty acids; 3 Diet high in 
fresh f uit and green, leafy vegetables (rich n antioxi ants and c rotenoids); 4 Consume oily fish ich in DHA and follow healthier eating styles e.g., Mediterranean 
diet; 5 A diet r ch in green l afy vegetables, fish and ntioxidants should be ncourag d; 6 Antioxidant nutrient supplements; 7a Age-Related Eye Disease Studies 
(AREDS) or AREDS2 supplement r comm nde ; 7b AREDS or AREDS2 supplement may be beneficial, and should be discussed in conjunction with the patient’s 
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Yes
Clinical Advisory Committee (United States) 2017
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fresh fruit and green, leafy vegetables (rich in antioxidants and carotenoids); 4 Consume oily fish rich in DHA and follow healthier eating styles e.g., Mediterranean 
diet; 5 A diet rich in green leafy vegetables, fish and antioxidants should be encouraged; 6 Antioxidant nutrient supplements; 7a Age-Related Eye Disease Studies 
(AREDS) or AREDS2 supplement recommended; 7b AREDS or AREDS2 supplement may be beneficial, and should be discussed in conjunction with the patient’s 
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4
Nutrients 2019, 11, 823 8 of 15 
Tabl  4. Nutritional recommendati ns for secondary r venti n ( .e., slowi g the progression) of age-related cular degenerati n (AMD). 
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or Miner l 
Supple ents  
Use f 
mega-3 Fatty 
Acid 
Supplements 
Contraindications 
or S de Effects of 
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Syste atic Review 
Cited with a 
Recommendation 
A erican Optical Assoc ation 2004 NR 6 None 
I tern tional Council of Ophthalmology 2007 NR R 
Spanish Retina and Vitreous Society 2009 1 7a  None 
Ca adian Expert Consensus 2012 2 a  Yes 
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Ey  Health C uncil of Ontario (Ca ada) 2015 3 7a 10  one 
National H th Committee (New Zealand) 2015 R 7a NR  e 
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Clinical Advisory Committe  (United States) 2017 4 7a 9 NR None 
NICE Guideline (NG82) 2018 NR 8 10  Y s 
Opto etry Australia 2019 5 7b NR NR None 
Abbreviatio s: , e omm ndati n includ d; NICE, National Institute for H alth and Care Excellence; NR, no recommendation. Guideline recommendations: 1 Diet
rich in c rotenoids (lutein and ze xanthin) and omega-3 fatty cids; 2 Die ary intake of a tioxidants, docosahexaenoic acid, and ome a-3 fatty acids; 3 Diet high in 
fresh fruit and gree , leafy vege ables (rich in antioxidant  and carotenoids); 4 Consume oily fish rich in DHA and follow healthier eating styles e.g., Mediterranean 
diet; 5 A diet rich in gree  le fy vegetables, fish and antioxidants should be encou aged; 6 Antioxidant nutrient supplements; 7a Age-R lated Eye Disease Studies 
(AREDS) or AREDS2 supplement recommended; 7b AREDS or AREDS2 supplement may be beneficial, a d should be discussed in conjunction with the patient’s 
g neral medical practitioner. 8 No evidence that benefit of AREDS supplement outweighs the risk; 9 O ga-3 fatty aci  supplem nt r commended; 10 No evidence 
for benefit of o ga-3 fatty acid supplements. 
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Table 4. Nutritional recomm dations f r secondary pr v nt  (i.e., slowing the progression) of age-relat  macular degeneration (AMD).
Clinic l Guideline Dietary Advice 
Use of 
A tioxidant 
or Mineral 
Supplements  
Use of 
Omega-3 Fatty 
Acid 
Supplements 
Contraindications 
or Sid  Effects of 
Suppleme ts 
Systematic Review 
Cited with a 
Recommendation 
American Optical Assoc ation 2004 NR 6 NR  None 
I ternational Council of Ophthalmology 2007 NR 7a NR NR None 
panish Retina and Vitreous Society 2009 1 7a NR  None 
Canadian Expert Consensus 2012 2 7a NR  Yes 
German Ophthalmolog c l Society 2014 NR 7  10  Yes 
Eye Health Council of O tario (Cana a) 2015 3 7a 10  N ne 
ati nal Health Committee (New Zealand) 2015 NR 7a NR NR N ne 
A erican Academy of Ophthalmology 015 R 7a NR  Non  
Vitreo-Reti a S ciety of the Philippines 2016 NR 7a NR  None 
NICE Clinical Knowledge Su mary (CKS) 2016 3 7a NR  Yes 
Cli ical Advisory Committee (U ited States) 2017 4 7a 9 NR None 
NICE Guideline (NG82) 2018 NR 8 10  Yes 
Optometry Australia 2019 5 7b NR NR None 
Abbr iations: , ecommend tion includ d; NICE Nat onal Inst tute for He lth nd Care Excell nce; NR, no recommendation. Gu deline recommendations: 1 Diet 
rich in c rot oi s (lute  nd ze xanthin) and omega-3 tty ac s; 2 Dietary intak  of antioxidants, docosahexaenoic acid, and omega-3 fatty acids; 3 Diet high in 
fr sh fruit and green, leafy vegetables (rich n antioxidants and carot no ds); 4 Consum  ily fish rich in DHA and follow healthier eating styles e.g., Mediterranean 
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Table 5. Quality, measured in %, of the included AMD clinical guidelines, based on the six assessment domains of the Appraisal of Guidelines for Research and
Evaluation II (AGREE II) appraisal tool. The scores for each of the six domains were calculated by summing up all the scores of the individual items for that domain,
and then scaling the total as a percentage of the maximum possible score for each domain.
Clinical Guideline
AGREE II Domains (%)
Scope and
Purpose
Stakeholder
Involvement
Rigour of
Development
Clarity of
Presentation Applicability
Editorial
Independence
American Optical Association 2004 52.8 30.6 9.2 30.6 10.9 87.5
International Council of Ophthalmology 2007 58.3 30.6 10.2 58.3 2.2 0.0
Spanish Retina and Vitreous Society 2009 63.9 41.7 21.4 36.1 13.0 0.0
Canadian Expert Consensus 2012 75.0 47.2 36.7 75.0 28.3 20.8
German Ophthalmological Society 2014 30.6 25.0 19.4 52.8 0.0 0.0
Eye Health Council of Ontario (Canada) 2015 61.1 22.2 14.3 41.7 13.0 20.8
National Health Committee (New Zealand) 2015 75.0 13.9 20.4 55.6 30.4 0.0
American Academy of Ophthalmology 2015 83.3 63.9 72.4 94.4 17.4 75.0
Vitreo-Retina Society of the Philippines 2016 83.3 44.4 56.1 88.9 13.0 45.8
NICE Clinical Knowledge Summary (CKS) 2016 88.9 83.3 68.4 91.7 39.1 87.5
Clinical Advisory Committee (United States) 2017 52.8 22.2 9.2 44.4 4.3 0.0
NICE Guideline (NG82) 2018 94.4 88.9 95.9 100.0 97.8 100.0
Optometry Australia 2019 83.3 41.7 19.4 75.0 19.6 0.0
Median (range)
75.0
(range 30.6 to
94.4%)
41.7
(range 13.9 to
88.9%)
20.4
(range 9.2 to
95.9)
58.3
(range 30.6 to
100%)
13.0
(range 2.2 to
97.8%)
20.8
(range 0 to
100%)
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4. Discussion
Nutritional supplements for ‘eye health’ are marketed at the general population, and are also widely
recommended by optometrists and ophthalmologists for people who have clinical signs of AMD [37,38].
Clinical practice guidelines are a useful method for presenting evidence-based recommendations to
health care professionals, and are intended to be used to inform clinical decision-making and reduce
potential variations in practice. The aims of the current study were to identify all clinical guidelines for
AMD that include recommendations relating to diet and/or nutrition; to evaluate the methodological
quality of these guidelines using the AGREE II tool (the most widely used instrument for appraising
clinical practice guidelines); and to investigate whether specific nutritional recommendations were
underpinned by evidence from systematic reviews.
We identified 13 clinical practice guidelines meeting our inclusion criteria. The overall quality
of these guidelines was judged to be low to moderate, with the median percentage scores for four
of the six AGREE II quality domains being below 50%. The lowest scoring domains were ‘Rigour
of Development’, ‘Applicability’, and ‘Editorial Independence’. Low scores in these domains are of
major concern, as they relate to: the process by which relevant research evidence is gathered and
synthesised; the methods used to formulate the recommendations; the likely barriers and facilitators to
implementation of the guideline recommendations; and how conflicts of interest are managed. It is
important that guideline users are able to identify the evidence underpinning each recommendation,
however many of the guidelines failed to make an explicit link to the evidence used to formulate
recommendations. Transparency with respect to the reporting of conflicts of interest amongst guideline
development panels is also essential, to avoid the potential for biased recommendations. Patient
engagement in the development of the clinical practice guidelines was also generally poor, despite
standards (including those defined by the World Health Organisation) [39] recommending the inclusion
of patients on guideline development panels. The intent of this engagement is to ensure a focus on
patient-centred guidelines that can enhance the quality of care [40].
Only one guideline (the National Institute for Health and Care Excellence (NICE) guideline NG82)
achieved high scores in all of the AGREE II assessment domains. This is perhaps unsurprising, since
the NICE guideline development manual states that NICE guidelines “are based on internationally
accepted criteria of quality as detailed in the Appraisal of Guidelines of Research and Evaluation II
(AGREE II) instrument”. The development and implementation of high quality clinical practice
guidelines requires substantial time, expertise and resources. Less formal guideline development
groups, such as those produced by ‘expert panels’ or professional organisations, may lack the resources
and/or methodological expertise to produce guidelines of the highest quality. In such circumstances,
adapting existing high quality guidelines to local contexts may be an alternative to de novo development.
The AMD Preferred Practice Patterns (PPP) Philippines (2016) [35] is an example of where this strategy
has been adopted. This guideline was prepared by a panel from the Vitreo-Retina Society of the
Philippines for the Philippine Academy of Ophthalmology, by adapting recommendations from the
American Academy of Ophthalmology (AAO) PPP for AMD (updated in 2015).
Many robust systematic reviews have considered the merit of a variety of dietary and nutritional
recommendations for AMD. In the present study, we used the systematic evidence searches performed
by Lindsley et al. [11] and Downie et al. [12] to identify relevant systematic reviews, up to March 2017.
These studies identified 11 unique systematic reviews on nutritional interventions for AMD, published
between 2007 and 2016. Four of these reviews were published in the Cochrane Library. Mapping of
clinical practice guideline recommendations to systematic review evidence showed that four of the
included guidelines [24,25,30,34] made reference to systematic reviews to support their nutritional
recommendations. Other guidelines included evidence from individual RCTs or non-randomised trials
only. In some cases, recommendations were provided with no supporting citations. Although it is
likely that a proportion of the systematic review evidence would not have been available to the panels
developing the three earliest guidelines, published between 2004-2009 [26,33,36], this evidence would
certainly have been available to later panels and could have been used to inform their recommendations.
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Inconsistent uptake of evidence from systematic reviews by decision-makers and guideline developers
is known to be related to several factors, including lack of awareness, lack of access and lack of
familiarity [41]. The outcome of failing to use the best-available research evidence (i.e., systematic
reviews) to inform practice guidelines is that this time-intensive, rigorous research effort is wasted.
Furthermore, the entire rationale for the guideline to support evidence-based practice, and optimise
patient outcomes is potentially not achieved.
Of the nine guidelines that considered nutritional approaches for the primary prevention
of AMD, most considered the potential merit of dietary modification, although some also made
recommendations in relation to nutritional supplementation. Several epidemiological studies have
investigated whether specific dietary patterns and/or foods are associated with a reduced risk of
developing AMD. A meta-analysis of prospective cohort, case-control and cross-sectional studies
concluded that consumption of two or more servings of oily fish per week was beneficial in the primary
prevention of AMD [13]. Another recent systematic review reported that a high consumption of
vegetables rich in carotenoids and oily fish containing omega-3 fatty acids was beneficial for those
at risk of AMD [42]. However, emphasising the potential difference in nutritional benefit(s) derived
from whole foods versus supplementation, consuming anti-oxidant supplements does not prevent
the primary onset of AMD [16]. It is therefore concerning that a recent (2017) U.S. ‘guideline’ [28],
produced by a panel of optometrists, recommended prescribing xanthophil supplements (i.e., lutein,
zeaxanthin and mesozeaxanthin) to patients with ‘sub-clinical’ AMD, as “it is better to prescribe a
supplement than not to prescribe a supplement”. Although termed a ‘guideline’, this document
achieved the poorest quality scoring of all those included, with characteristics of a ‘clinical viewpoint’
rather than a ‘guideline’ per se.
Nutritional strategies for secondary prevention of AMD (i.e., slowing progression of the disease)
were included in all of the clinical guidelines. Five guidelines [24,28,33,34] included dietary advice,
consisting of recommendations for people with AMD to eat a healthy balanced diet and, specifically to
increase the consumption of foods rich in the macular carotenoids and/or eat more fish (as a source of
omega-3 fatty acids). A Mediterranean diet has been linked to a reduced risk of AMD progression [43].
Epidemiological studies suggest that a high dietary intake of omega-3 fatty acids is associated with a
significant reduction in the risk of both intermediate [44,45] and late-stage AMD [46,47]. However,
the best-available research evidence does not support long-chain omega-3 fatty acid supplementation
for slowing disease progression [15]. Despite this, and acknowledging that there is a lack of evidence
to substantiate such a position, two recent clinical guidelines [28,34] included a recommendation for
clinicians to consider this approach.
With respect to high-dose anti-oxidant vitamin and mineral supplements for managing AMD,
there were divergent recommendations. Notably, only the U.K. NICE guideline [25] did not advocate
prescribing supplements containing the formulation of antioxidant vitamins, zinc and carotenoids
investigated in the Age-Related Eye Disease Studies (AREDS [7] and AREDS2 [8]). This recommendation
was based upon the committee’s assessment of the limitations of the current, best-available evidence,
and a need for “further research in this area”. Indeed, there remain several key unanswered questions.
For example, the minimum effective dose required for a given antioxidant to impart a potential
retinoprotective effect remains unclear. Whether a single component, or a combination of components,
represents the optimal formulation is also uncertain. The NICE guideline committee recommended
“a well conducted randomised trial [ . . . ] to provide an evidence base for the benefits and risks
of individual components of the antioxidant supplements, and provide the ability to establish the
treatment effect of antioxidant supplementation (the AREDS2 formula) on AMD progression by
comparing AREDS2 formula with no treatment (for instance normal diet)”. Although many of the
guidelines considered the potential contraindications and/or side effects of high-dose antioxidant
vitamin and mineral supplements, four of the guidelines did not articulate these risks [28,31,32,36].
Given that the decision to prescribe an intervention should balance the potential risks versus benefits
of treatment, lack of this key information to guide clinical decision-making is a major shortcoming.
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A key strength of the current study was the comprehensive search to identify eligible clinical
practice guidelines. Data extraction and quality appraisal were conducted independently by two
reviewers, using a recognised assessment tool (AGREE II), which has established metrics of reliability
and validity [48]. Overall, the reporting of methodological details for clinical guideline development
was poor and therefore it was not possible to make a judgement as to whether the guidelines had used
an appropriate evidence-based approach in their development.
5. Conclusions
Despite the availability of robust systematic reviews evaluating the efficacy and safety of
nutritional interventions for AMD, this study found evidence that these resources are infrequently
used to support recommendations in AMD clinical practice guidelines. Consequently, guidelines
often present conflicting recommendations that could lead to variations in clinical care. The AGREE II
quality evaluations of the included guidelines identified several key areas that require improvement,
particularly the rigour of development, managing potential conflicts of interests, and presenting
strategies for implementing guideline recommendations into daily practice.
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